HER-2 overexpression

This multicenter retrospective study included 290 female patients diagnosed with HER2-positive early or locally advanced breast cancer treated with neoadjuvant trastuzumab and pertuzumab-based regimens (anthracycline-based [AC-THP] or non-anthracycline [TCHP]) across six centers. pCR remains the strongest surrogate for survival, neutralizing initial risk factors. These findings support using quantitative biomarker thresholds for personalization and reinforce the efficacy of non-anthracycline regimens.

Benign salivary gland tumors represent a valuable model for studying malignant transformation in head and neck oncology. Interpreting shared molecular and microenvironmental pathways may facilitate the identification of novel biomarkers and support the development of personalized diagnostic and therapeutic approaches for OSCC.

The overexpression of HER2 lays the groundwork for the possible use of anti-HER2 targeted drugs in this tumor type, particularly in adenocarcinomas. These findings provide baseline immunohistochemical data for feline nasal carcinomas and highlight HER2 as a relevant biomarker for future diagnostic and therapeutic research.

P2, N=60, Active, not recruiting, Hospices Civils de Lyon | Recruiting --> Active, not recruiting

HER2 overexpression exhibits stage-specific patterns, strongly linked to aggressive features and progression risk in NMIBC but primarily to lymphatic spread in MIBC/mUC. These findings provide preliminary evidence supporting HER2 as a stage-specific biomarker, with implications for risk stratification and emerging targeted therapies.

Although the sample size is small, these findings support the clinical benefit of zanidatamab treatment for HER2-positive SGC.

P2, N=30, Not yet recruiting, Sun Yat-sen University

P1/2, N=270, Completed, Dragonfly Therapeutics | Recruiting --> Completed | Trial completion date: Dec 2026 --> Dec 2025 | Trial primary completion date: Oct 2026 --> Dec 2025

These changes resulted in adjuvant treatment adjustments in 9/110 (8.18%) patients with residual disease. Changes in the expression of all immunohistochemistry biomarkers and BC subtypes occurred after NACT, which led to changes in adjuvant treatment in specific cases.

Our findings highlight the dual role of ATPIF1 in CAR-T cell therapy: while its overexpression boosts metabolic activity in vitro, its knockdown enhances adaptability to the hypoxic tumor microenvironment in vivo, indicating the paradox for modulating the antitumor activities of CAR-T cells via the metabolic remodeling for the treatment of solid tumor. These insights suggest that targeting ATPIF1 or the STING pathway could optimize CAR-T cell efficacy in solid tumors, bridging the gap between in vitro performance and in vivo outcomes.

Our findings indicate that COL1A2 is associated with reduced chemotherapy sensitivity in HR+/HER2- breast cancer and may serve as a candidate biomarker to guide neoadjuvant taxane selection. This study provides a novel theoretical basis for optimizing neoadjuvant chemotherapy regimens in patients with advanced HR+/HER2- breast cancer.

These cases suggest that systemic HER2-targeted therapy can serve as an effective neoadjuvant approach for locally advanced HER2-positive SGCs. Conversion surgery following Tmab and DTX treatment may offer a curative option in selected patients initially deemed inoperable.